Back to OGNView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
View Full LandscapeDrug Information
Target Indication
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Clinical Trial
NCT00338260Last updated: 6/26/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
MK0663, Etoricoxib / Duration of Treatment : 12 WeeksPhase 3
Recurrent Low Back Pain
MK0217, alendronate sodium / Duration of Treatment : 2 YearsPhase 3
Osteoporosis, Postmenopausal
Tibolone 2.5 mgPhase 3
Postmenopausal Women
Corifollitropin alfaPhase 3
In Vitro Fertilization
A-Phase: tirofiban; Z-Phase simvastatinPhase 3
Acute Coronary Syndrome
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts